Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM 7: Belantamab Mafodotin vs Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT04246047Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- May 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoint: Progression-free Survival at 41 months. Started May 2020; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04246047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246047.